Common antifungal drug may help prevent esophageal cancer recurrence
NCT ID NCT05609253
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial investigates whether itraconazole, a common antifungal medication, can reduce the risk of cancer in people with high-risk Barrett's esophagus who have already undergone endoscopic ablation. Barrett's esophagus often returns after treatment, increasing the chance of esophageal cancer. The study will measure drug levels in blood and tissue, and check for side effects, in 10 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Itraconazole
- What this could lead to
- If it works, this could point toward a way to prevent Barrett's esophagus from coming back after treatment, lowering the risk of esophageal cancer.
- What could go wrong
- This is a very early, small study (10 people) focused on drug levels and safety, not yet on preventing recurrence. Itraconazole also has side effects and may not prove effective in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BARRETT OESOPHAGITIS WITH DYSPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.